Compare TDW & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDW | CRNX |
|---|---|---|
| Founded | 1956 | 2008 |
| Country | United States | United States |
| Employees | 7300 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | TDW | CRNX |
|---|---|---|
| Price | $78.25 | $83.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $81.33 | $76.75 |
| AVG Volume (30 Days) | 651.6K | ★ 6.8M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $8.44 | $720.10 |
| Revenue Next Year | $12.34 | $184.67 |
| P/E Ratio | $24.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.65 | $25.83 |
| 52 Week High | $93.13 | $84.00 |
| Indicator | TDW | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 62.88 | 92.07 |
| Support Level | $76.82 | $33.50 |
| Resistance Level | $88.24 | N/A |
| Average True Range (ATR) | 2.75 | 0.18 |
| MACD | 0.89 | -0.10 |
| Stochastic Oscillator | 88.16 | 53.51 |
Tidewater Inc provides marine and transportation services to the offshore energy industry. The company's vessels and associated services support all phases of offshore crude oil and natural gas (also referred to as oil and gas) exploration activities, field development, production, and maintenance, as well as windfarm development and maintenance. Its services include towing and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workovers, production activities, field abandonment, dismantlement, and restoration activities; and Others. The group manages its business through five segments, including the Americas, Asia Pacific, Middle East, Europe/Mediterranean, and West Africa.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.